(MYGN) Myriad Genetics, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MYGN) Myriad Genetics, Inc. Complete Analysis Pack
Your Credibility Toolkit Starts Here
This Myriad Genetics, Inc. SWOT Analysis summarizes the company’s strengths, weaknesses, opportunities, and threats to help with research, strategy, or investment decisions; the page already includes a real preview/sample so you can judge format and depth before buying. Purchase the full version to unlock the complete ready-to-use analysis.
Strengths
Diversified 3-Segment Test Portfolio
Myriad Genetics spreads risk across oncology, women’s health, and mental health, so weakness in one test line does not depend the whole business. In fiscal 2025, that mix helped support revenue across multiple care paths, with the company reporting about $800 million in annual sales. One diagnostics platform serving three specialties also gives Myriad Genetics more shots at cross-selling and payer coverage.
Multiple Commercial Tests in Market
Myriad Genetics, Inc. sells eight branded tests, including MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Prequel, Foresight, and GeneSight. That broad menu gives the Company a wide clinical footprint across oncology, prenatal, and mental health testing. A large installed base supports repeat use, stronger brand recall, and steadier test demand.
Companion Diagnostic Capability
BRACAnalysis CDx and MyChoice CDx help guide cancer treatment choices, so they sit inside real clinical workflows and precision medicine use. Myriad Genetics, Inc. has 2 key companion diagnostics that can deepen physician reliance on its testing for therapy selection, especially in breast and ovarian cancer. This gives the company a sticky, decision-linked strength that is harder to replace than routine lab tests.
Established Since 1991
Founded in 1991, Myriad Genetics, Inc. brings 34 years of operating history into FY2025, which helps build trust with clinicians, payers, and lab partners. Its long U.S. base in Salt Lake City, Utah, also supports a stable domestic footprint for genetics testing and commercialization.
That kind of tenure matters in a regulated market: it signals staying power, experience with reimbursement, and familiarity with clinical adoption cycles.
- Founded in 1991
- 34 years of history in FY2025
- Headquartered in Salt Lake City, Utah
- Supports credibility with U.S. stakeholders
Strategic Partnerships with Illumina and Intermountain
Myriad Genetics, Inc.'s links with Illumina, Inc. and Intermountain Precision Genomics give it access to high-scale next-generation sequencing and a wider clinical channel. Illumina posted $4.33 billion in FY2025 revenue, underscoring the platform depth behind Myriad's testing stack. That reach helps Myriad support both germline and somatic tumor testing.
- Better tech access
- Broader test scale
- Stronger clinical reach
- Supports two test types
Myriad Genetics’ Broad Test Mix Fuels $800M Sales and Durable Trust
Myriad Genetics, Inc. has a broad test mix across oncology, women’s health, and mental health, which reduced single-line risk in FY2025 and supported about $800 million in annual sales. Its eight branded tests, led by MyRisk, BRACAnalysis CDx, MyChoice CDx, and GeneSight, give the Company a wide clinical footprint. Companion diagnostics and 34 years of history strengthen payer trust and physician stickiness.
| Strength | FY2025 data |
|---|---|
| Revenue scale | About $800 million |
| Branded tests | 8 |
| Operating history | Founded 1991 |
| Headquarters | Salt Lake City, Utah |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Myriad Genetics, Inc.’s business strategy
Editable Excel File
Provides a quick SWOT snapshot for Myriad Genetics, Inc., making strategic gaps and opportunities easy to spot.
Reference Sources
Cites primary industry reports, government datasets, and peer-reviewed studies to validate Myriad Genetics’ market, pricing, and competitive assumptions.
Weaknesses
High Dependence on Reimbursement
Myriad Genetics, Inc. depends heavily on payer coverage, so any reimbursement cut can hit test volumes fast. In 2025, genetic testing still faced tight pricing from Medicare and private insurers, which keeps gross margin and revenue sensitive to third-party decisions. That leaves Myriad Genetics, Inc. with limited control over pricing power.
Narrow Core Business Concentration
Myriad Genetics, Inc. still relies mainly on diagnostics and precision medicine, with FY2025 revenue still under $1 billion, so it lacks the mix of drugs, devices, and services that larger life science firms use to smooth shocks. That narrow base means a weak testing cycle can hit results fast. A slowdown in hereditary cancer or prenatal test volume can ripple straight through the whole P&L.
Heavy Reliance on Clinical Adoption
Myriad Genetics’ weakness is its heavy reliance on clinical adoption, since tests like GeneSight, Prolaris, and hereditary cancer screening need physician recommendation and guideline support. In FY2025, the Company still depended on routine use in oncology and prenatal care to drive growth, so slow uptake can cap revenue even when test performance is strong. If doctors do not adopt at scale, sales can lag demand for years.
Complex Evidence Requirements
Myriad Genetics, Inc. faces heavy proof demands because genetic tests only gain broad acceptance when clinical utility is clear. That means constant spend on outcomes studies and payer evidence, adding to execution risk; FY2025 revenue was about $0.8B, so every extra study dollar hits a still-scaled business.
- Clinical utility must stay proven
- Evidence work raises fixed costs
- Payer access depends on data
Exposure to Regulatory and Compliance Burden
Myriad Genetics, Inc. works in a tightly regulated diagnostics market, so CLIA lab rules, FDA oversight, and HIPAA privacy duties can slow product launches and lift costs. The risk is real: in FY2025, every delayed assay update or compliance fix can hit margins and cash flow, while any lapse can weaken trust with providers and payers.
- Slower launches.
- Higher compliance spend.
- Trust risk with payers.
- Privacy or lab failures hurt adoption.
Myriad Genetics Faces Payer Pressure and Narrow Diagnostics Exposure
Myriad Genetics, Inc. is weak on pricing power: FY2025 revenue was about $0.8B, and payer cuts can hit test volumes fast. Its narrow mix in diagnostics leaves results exposed to any slowdown in hereditary cancer or prenatal testing. It also needs steady physician adoption and costly evidence work to support coverage.
| Weakness | FY2025 data |
|---|---|
| Revenue scale | About $0.8B |
| Payer risk | High |
| Mix concentration | Diagnostics only |
What You See Is What You Get
Myriad Genetics, Inc. Reference Sources
This is the same SWOT analysis document included in your download—professional, structured, and ready to use; the preview below is taken directly from the full report you'll receive after purchase.
Opportunities
Expanding Precision Oncology Demand
U.S. cancer diagnoses are projected at 2.04 million in 2025, and that keeps demand for biomarker-driven testing rising. Myriad Genetics, Inc. can benefit as hereditary risk, companion diagnostics, and tumor profiling move deeper into routine care. More targeted treatment pathways should lift test use and widen the addressable market.
International Market Expansion
Myriad Genetics already sells in the U.S. and overseas, so broader global use of genetic testing can add a second revenue stream. That matters because international sales can help offset U.S. reimbursement swings, which still drive a large share of Company revenue.
As more health systems adopt genomic testing, Myriad can grow with a much larger addressable market and lower concentration risk.
Women’s Health Screening Growth
Prequel and Foresight target prenatal and carrier screening for the roughly 4 million U.S. births each year, so even modest adoption gains can add volume. As preventive testing awareness rises, Myriad Genetics can reach more patients and providers. Women’s health is still underpenetrated, which leaves room for faster screening uptake and better long-term growth.
Mental Health Pharmacogenomics Adoption
GeneSight gives Myriad Genetics, Inc. a clear edge in depression, anxiety, and ADHD by helping clinicians match drugs to patient genetics. That matters as U.S. depression affects about 29 million adults and ADHD about 11 million, so even small gains in fit can lift adoption. Wider use of pharmacogenomic testing could deepen Myriad Genetics, Inc.’s role in behavioral health.
- Targets high-volume mental health care
- Supports better drug selection
- Can widen behavioral-health demand
New Data and Workflow Partnerships
Myriad Genetics can expand deals like Illumina and Intermountain to speed assay development and reach more sites. Illumina reported 2025 revenue of about $4.4 billion, showing how big platform ties can be, while Myriad’s own growth depends on making tests easier to order, run, and act on inside provider workflows.
Digital links to EHRs and lab systems can make Myriad Genetics harder to replace and raise repeat use. That matters in a market where faster clinical integration can cut turnaround time and improve adoption across oncology and hereditary testing.
- More platform partners
- Faster assay rollout
- Better provider stickiness
- Stronger data workflow ties
Myriad’s Growth Runs Through Cancer, Births, and Mental Health
Myriad Genetics, Inc. can gain from rising 2025 U.S. cancer diagnoses at 2.04 million and wider use of biomarker-driven care. Prequel, Foresight, and GeneSight also sit in large pools: about 4 million U.S. births, 29 million adults with depression, and 11 million with ADHD.
Global genomic adoption and payer-backed access can lift volume and reduce U.S. reimbursement risk.
| Opportunity | 2025/2026 data |
|---|---|
| Oncology | 2.04M U.S. cancer cases |
| Women’s health | 4M U.S. births |
| Behavioral health | 29M depression; 11M ADHD |
Threats
Intense Competition in Genetic Testing
Myriad Genetics, Inc. faces intense competition from large diagnostics firms and niche molecular test rivals, which can squeeze pricing, physician share, and payer coverage. In a market where faster assay launches and broader test menus can shift referrals quickly, Myriad must keep innovating to protect its hereditary cancer and prenatal testing positions. If rivals win reimbursement first, Myriad’s market share and margins can fall fast.
Reimbursement and Coverage Volatility
Myriad Genetics, Inc. faces real payer risk because coverage rules can change fast for hereditary cancer and other genetic tests. A narrower policy or lower fee schedule can hit a business where reimbursement is the main revenue driver, and even small cuts can press margins because test costs are partly fixed.
If payors trim coverage or push down rates, Myriad Genetics, Inc. can lose volume and price at the same time, which is the worst mix for earnings.
Regulatory Tightening
Regulatory tightening is a real risk for Myriad Genetics, Inc. Genetic tests face closer FDA and payer scrutiny, so each new assay can need more validation and documentation, which lifts cost and slows launch timing. In FY2025, Myriad Genetics, Inc. reported $821.3 million in revenue, so even small delays in expansion can hit growth and margin plans.
Rapid Technology Change
Rapid tech change is a real threat for Myriad Genetics, Inc.: sequencing methods, panel design, and variant interpretation tools keep moving, so older assays can look slow or less accurate. In the oncology testing market, even a small lag can push labs and clinicians to newer platforms with faster turnaround and broader coverage. Myriad Genetics must keep funding R&D and updates or risk losing share.
- Lagging assays can drive provider switch risk.
- Continuous platform upgrades are essential.
- Speed and interpretation quality shape demand.
Data Privacy and Security Risk
Genetic data is among the most sensitive personal data, so any breach can trigger lawsuits, fines, and lost trust. U.S. healthcare breaches exposed about 168 million records in 2024, showing how costly security lapses can be. For Myriad Genetics, Inc., trust is critical in hereditary and mental health testing, where patients expect strict privacy.
- High breach costs
- Legal and regulatory risk
- Reputation damage
- Trust loss in testing
Even one cybersecurity failure can slow orders, raise compliance costs, and hurt retention. Privacy concerns can also reduce patient willingness to share family history, which can weaken test accuracy and demand.
Myriad Faces Payer Pressure, Fierce Competition, and Cyber Risk
Myriad Genetics, Inc. is exposed to heavier payer pressure as coverage rules and fee schedules can shift fast, and even small cuts can hurt a reimbursement-led model. FY2025 revenue was $821.3 million, so slower coverage or lower rates can quickly dent growth and margins.
Competition is another threat: larger diagnostics firms and faster test rivals can win physician share, especially if they launch broader panels or faster assays first.
Cyber and regulatory risk also matter, since genetic data is highly sensitive and U.S. healthcare breaches exposed about 168 million records in 2024.
| Threat | Latest data | Impact |
|---|---|---|
| Payer cuts | FY2025 revenue: $821.3M | Margin and volume risk |
| Cyber risk | 168M records exposed in 2024 | Trust and legal risk |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.